Background and Objective: There is marked controversy regarding optimal management patients with stage IB grade III endometrial carcinoma. The present study analyzes the current practices regarding adjuvant radiation therapy for those patients in our institute and also assessed prognostic factor affecting overall survival outcome. Patients and Methods: A total 66 patients with postoperative FIGO stage 1B, grade III endometrial carcinoma were treated and evaluated between the years 2009 and 2014. Risk factors assessed age (<60 versus ≥60), tumor size (≤4 cm versus >4 cm), site of primary tumor (involvement of lower uterine segment versus no involvement), Lymphadenectomy (performed versus not performed), Lymph-vascular space invasion (positive or negative), type of surgery performed (less than total abdominal hysterectomy and bilateral salpingo-ophorectomy (TH/BSO) versus greater than or equal TH/BSO), radiation sequence with surgery (no radiation versus adjuvant radiation), and type of radiation (pelvic external beam radiotherapy versus vaginal brachytherapy versus both). Results: Adjuvant radiation therapy after surgery was associated with significantly better time to relapse (p = 0.001) in comparison to those patients who underwent surgery alone. There was statistically significant improvement of survival of patients who received adjuvant radiation therapy in comparison with those who underwent surgery alone. There was no statistically significant difference in relapse between external pelvic radiotherapy, brachytherapy and both (p = 0.161). There was no statistically significant difference in overall survival between different types of adjuvant radiation therapy (p = 0.318). Adjuvant radiation therapy (HR 0.173, 95% CI 0.049 -0.609, p = 0.006) and tumor size (HR 4.065, 95% CI 1.120 -14.761, p = 0.033) were the only statistically significant predictors for relapse in multivariate analysis. Adjuvant radiation therapy (HR 0.159, 95% CI 0.045 -0.563, p = 0.004), age (HR 10.357, p = 0.034) and lymphadenectomy (HR 0.240, 95% CI 0.071 -0.811, p = 0.022) were statistically significant predictors for overall survival. Conclusion: The current
Introduction
Endometrial cancer is the most sixth common neoplasm in women worldwide [1] . Mostly, endometrial cancer occurs over the age of fifty with a median age at diagnosis of 63 years [2] . Most of endometrial cancers are diagnosed at early stage (80% in stage I) [3] .
Endometrial carcinoma has been classified into two main clinic-pathological and molecular types; type I is the most common (80% -90%) endometrioid adenocarcinoma and type II consists of non endometrioid subtypes (10% -20%) such as clear cell, serous and undifferentiated carcinomas in addition carcinosarcoma/malignant-mixed Mullerian tumor [4] .
Histopathologically, endometrioid is classified into three grades; 1, 2 and 3.
Due to high possibility of local recurrence, lymph node and distant spread, grade 3 is considered high grade [5] .
In accordance with FIGO (The International Federation of Gynecology and Obstetrics) staging for endometrial cancer, stage 1 disease was further sub classified depending on the depth of tumor invasion because this is considered to be an adverse risk factor for disease outcome. In 2009, FIGO staging updated the previous 1988 version. Stage I subdivided into Stage IA included tumors with less than 50% myometrial invasion and stage IB included tumors with more than 50% myometrial invasion, with omission of stage IC, which previously included tumors with more than 50% myometrial invasion. Therefore, prior stage IC is equal to the current stage IB [6] .
Patients with stage I endometrial cancer is mainly treated with surgery. Because of low risk of local recurrence and distant metastasis, surgery alone with or without vaginal brachytherapy is often the treatment of choice of stage IA with excellent outcomes [7] [8] .
Outcome of patients with stage IB widely differ. Their outcome depends on grade of tumor and presence or absence of risk factors which previously identified in large prospective trials, including age, tumor size and lymphovascular space invasion (LVSI) [9] [10] .
Treatment recommendation of the major evidenced based guidelines on endometrial cancer is heterogeneous. For example, The American Society of Clini- Accordingly, there is marked controversy regarding optimal management patients with stage IB grade III endometrial carcinoma. The present study analyzes the current practices regarding adjuvant radiation therapy for those patients in our institute and also assessed prognostic factor affecting overall survival outcome.
Patient & Methods
After Inclusion criteria:
Patients of any age with a histologically proven endometrioid carcinoma postoperative FIGO stage IB grade 3 were eligible for the study (stage IB included tumors with more than 50% myometrial invasion). Poorly or un-differentiated endometrioid carcinomas were also included in our analysis.
Exclusion criteria:
Patients for whom the radiation sequence with surgery was unknown or lost follow up also excluded from the study. Follow up: Chest X-ray and abdominal-pelvic CT or MRI were conducted every six months for the first two years post-surgery and then annually.
Statistical analysis: Data were entered and analyzed using IBM-SPSS software (Version 25.0. Armonk, NY: IBM Corp.). Qualitative data were expressed as frequency and percentage. Quantitative data were initially tested for normality using Kolmogorov-Smirnov and Shapiro-Wilk's test with data being normally distributed if p > 0.050. Quantitative data were expressed as mean ± standard deviation (SD). Qualitative data were compared by Chi-Square test (or Fisher's exact test). Monte Carlo significance was used when appropriate. Bonferroni method to adjust p values when comparing column proportions was also used. Quantitative data between two groups were compared by Independent-Samples t-test if data were normally distributed in both groups. The non-parametric alternative Mann-Whitney U test was used if not. Quantitative data between more than two groups were compared by One-way ANOVA test if data were normally distributed in all groups. The non-parametric alternative Kruskal-Wallis H test was used if not. Pairwise comparisons were performed if the result was significant to detect where that significant difference existed. The Kaplan-Meier method was used to estimate the probability of survival past given time points (i.e. it calculates a survival distribution). The survival distributions of two or more groups of a between-subjects factor can be compared for equality using log-rank test. Cox regression analysis was used to predict survival. For any of the used tests, results were considered as statistically significant if p value ≤ 0.050.
Results
This study included 66 patients with stage IB grade III endometrial carcinoma with mean age ± SD of 60.6 ± 6.1 years. Most of the patients underwent total abdominal hystrectomy and bilateral salpingo-oophrectomy, only 7.6% of patients underwent substandard surgery. Thirty seven tumors (56.1%) were larger than 4 cm. Twenty six tumors (39.4%) showed involvement of lower uterine segment. Most of the patients (74.2%) underwent lymphadenectomy. Lymphovascular space invasion (LVSI) was present in 34.8% of tumors, absent in 42.4% of tumors and not assessed in 22 In these trials, patients were randomized after surgery (total abdominal hysterectomy and bilateral salpingo-ophorectomy) to external beam radiation therapy or observation. The three trials and meta-analysis by Kong et al. [17] observed that external beam radiation therapy reduced risk of recurrence from 14% to 4%, but did not achieve any overall survival benefit and associated with significant morbidity.
PORTEC-1 trial [16] defined risk groups according risk factors for locoregional recurrence (age > 60 years, deep (≥50%) myometrial invasion, grade 3).
High-intermediate risk patients defined as presence of two of three of these risks.
GOG99 trial [7] Data from previous randomized trials provide strong evidence that adjuvant radiation therapy is improving local control, but not overall survival in patients with high grade deeply invasive stage I endometrial cancer. PORTEC-3 randomized trial was aiming to intensify treatment beyond radiation alone. The randomization was between adjuvant radiation therapy alone versus adjuvant che- been reported in this study [20] .
The current study presents information on practice pattern regarding the use of adjuvant radiation therapy for stage I grade III endometrioid adenocarcinoma of the uterus. In this study, 30% of patients did not receive adjuvant radiation therapy. Similarly a recent study from National Cancer Data Base (NCDB)
showed that 52% of patients with stage IB (any grade) did not receive adjuvant radiation therapy [21] .
This finding suggests discrepancy between national guidelines and common practice. This may be explained heterogeneity in groups of patients included in the previous clinical trials and heterogeneity in the treatment arms, making it difficult to define exactly which patients would gain the benefit from adjuvant radiation therapy.
The current study showed adjuvant radiation therapy after surgery was associated with statistically significant better local control and improvement of survival in comparison to those patients who underwent surgery. Similar observation was reported by Harkenrider et al. [22] . On the other hand, several randomized trials and meta-analyses did not show improvement of survival [17] . The first systematic review and meta-analysis showed a trend towards better survival in high risk patients treated with postoperative radiotherapy but this was not statistically significant [24] . This observation was lost after ASTEC-ENS results. The effect of vaginal brachytherapy alone is difficult to be clarified because only one randomized trial compared brachytherapy with observation among low risk patients [25] .
The PORTEC-1 was planned to detect five years survival benefit of 10% for adjuvant external beam radiotherapy. This trial included around 700 patients, but given the low event rates, would have required more than 2000 patients per arm [22] . The sample size and the event rate deficit were aggravated by inclusion of low grade minimally invasive tumors which had low risk for relapse with no need for adjuvant treatment. Furthermore PORTEC-1 excluded stage 1 grade III patients and only one third of the patients (132) were high risk criteria according to GOG-99 trial, despite the fact that this group accounted for two thirds of the cancer related deaths [5] . The current study observed that there was no statistically significant difference in relapse between external pelvic radiotherapy, vaginal brachytherapy and both. Also, there was no statistically significant difference in overall survival between different types of adjuvant radiation therapy. Similarly, PORTEC-2 trial stated that there was no difference in locoregional relapse or overall survival between vaginal brachytherapy and external beam radiotherapy for patients with endometrial cancer of high-intermediate risk [18] . The Surveillance, Epidemiology, and End Results (SEER) data base has been assessed the value of addition of vaginal brachytherapy after external pelvic radiotherapy in patients with high risk stage I and II endometrial carcinoma. There was no statistically difference in overall 5 year and 10 year survival for external pelvic radiotherapy and addition of brachytherapy to external pelvic radiotherapy [26] .
The current study analyzed factors potentially affected relapse and overall survival. The prognostic value of positive peritoneal washing is debatable.
The majority of studies found that positive peritoneal washings were independent prognostic factor [27] [28] [29] . Currently, the following factors were analyzed, treatment received, age, type of surgery, tumor size, lymphadenectomy and lymphovascular space invasion (LVSI). In multivariate analysis treatment (HR 0.173, 95% CI 0.049 -0.609, p = 0.006) and tumor size (HR 4.065, 95% CI 1.120 -14.761, p = 0.033) were the only statistically significant predictors for relapse. Schink et al. (10) stated that tumor size is negatively affect outcome.
Multivariate analysis of factors potentially affected overall survival found that treatment (HR 0.159, 95% CI 0.045 -0.563, p = 0.004), age (HR 10.357, 95% CI 1.195 -89.746, p = 0.034) and lymphadenectomy (HR 0.240, 95% CI 0.071 -0.811, p = 0.022) were statistically significant predictors for overall survival. Many studies showed that age is important predictor for survival [7] [14] [18] . A study by Chino et al. [30] assessed the effect of radiation modality and lymph node dissection on survival in early stage endometrial cancer including stage IB, grade III. The authors stated that both lymph node dissection and adjuvant radiation improved overall survival.
Conclusion
Despite that this study is retrospective study with limited number of cases, it highlights the variation in the current practice in the management of patients with stage IB, grade III endometrioid carcinoma of the uterus. The current study suggested that adjuvant radiation therapy definitely improve survival of patients with stage IB, grade III. There is a need for more randomized trials to define patients who require adjuvant radiation therapy and define what type of radiation should be received. Well defined guidelines are very important to standardize treatment and cut costs in clinical practice.
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